Department of Medicine I, University Hospital Munich, Ludwig Maximilians University, Marchioninistr. 15, E81377, Munich, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
Sci Rep. 2021 Dec 21;11(1):24383. doi: 10.1038/s41598-021-03667-0.
Conduction disorders with need for permanent pacemaker (PPM) implantation remain frequent complications after transcatheter aortic valve implantation (TAVI). Up to 22% of PPM after TAVI are implanted for new onset left bundle branch block (LBBB) and atrioventricular block (AVB) I. However, clinical benefit and predictors of ventricular pacing in TAVI patients receiving PPM for this indication remain unclear. We retrospectively evaluated pacemaker interrogation data of patients who received a PPM post TAVI for new LBBB and new AVB I. The primary endpoint of this study was relevant ventricular pacing (ventricular pacing rate: Vp ≥ 1%) at the first outpatient pacemaker interrogation. Secondary endpoints were predictors for relevant ventricular pacing. At the first pacemaker interrogation (median follow up at 6.23 [2.8-14.8] months), median ventricular pacing frequency was 1.0% [0.1-17.8]. Out of 61 patients, 36 (59%) had Vp rates ≥ 1%. Patients with frequent ventricular pacing showed longer QRS duration (155 ms ± 17 ms vs. 144 ms ± 18 ms, p = 0.018) at the time of PPM implantation and were less likely treated with a balloon-expandable Edwards Sapiens Valve (39% vs. 12%, p = 0.040). Our findings suggest that the majority of patients with new LBBB and new AVB I after TAVI show relevant ventricular pacing rates at follow up. Further prospective studies are necessary to identify patients at higher risk of pacemaker dependency.
传导障碍需要植入永久性起搏器(PPM)仍然是经导管主动脉瓣植入(TAVI)后的常见并发症。多达 22%的 TAVI 后 PPM 是由于新发左束支传导阻滞(LBBB)和房室传导阻滞(AVB)I 而植入的。然而,对于因这种适应证而接受 PPM 的 TAVI 患者,心室起搏的临床获益和预测因素仍不清楚。我们回顾性评估了因新发 LBBB 和新发 AVB I 而接受 TAVI 后 PPM 的患者的起搏器询问数据。本研究的主要终点是首次门诊起搏器询问时的相关心室起搏(心室起搏率:Vp≥1%)。次要终点是相关心室起搏的预测因素。在第一次起搏器询问时(中位数随访 6.23 [2.8-14.8] 个月),中位心室起搏频率为 1.0% [0.1-17.8]。在 61 名患者中,有 36 名(59%)Vp 率≥1%。心室起搏频繁的患者在植入 PPM 时 QRS 持续时间更长(155ms±17ms vs. 144ms±18ms,p=0.018),且不太可能使用球囊扩张 Edwards Sapiens 瓣膜治疗(39% vs. 12%,p=0.040)。我们的研究结果表明,大多数因 TAVI 后新发 LBBB 和新发 AVB I 的患者在随访时存在相关的心室起搏率。需要进一步的前瞻性研究来确定具有更高起搏器依赖风险的患者。